Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services... see more

OTCPK:MEDVF - Post Discussion

Medivolve Inc > Revenue in Q2 +/- $ 12 million
View:
Post by Hiddensecrets on Jun 11, 2021 12:31pm

Revenue in Q2 +/- $ 12 million

I am expecting Q2 revenue of +/- $ 12 million in Q2.

That would bring our total revenue rate to $ 23 million in 6 months.

Forecast is for $ 60 million in year 2021.

David Preiner is very quiet, very different from Doug Sommerville.   He will allow the numbers to speak for themselves. 

mpo
Comment by gameofgainz on Jun 11, 2021 3:47pm
and where would that 12mil come from? David predicted 1 mil on covid testing per month... dont see anything else bringing i revs right now...
Comment by Hiddensecrets on Jun 11, 2021 5:16pm
Very recent presentation by David Preiner, only a few weeks old, forecasted revenue of $ 60 million in 2021.  Forecast was made in late May 2021. We had revenue of $ 11 million Q1 which means that we need $ 49 million from the other 3 quarters. David is a very conservative person and he will not throw out numbers out there for the sake of throwning them out.    When he did the ...more  
Comment by gameofgainz on Jun 11, 2021 8:08pm
im very hopefull, but nuturell isnt on that presentation, additxt isnt being offered yet and so far neither is any telediagnostics. If david isnt one to throw out random numbers, he might need to explain where he is pulling them from. So far im not seeing it.
Comment by Sarb99 on Jun 11, 2021 10:16pm
I asked that question from the management and here is reply  Hello *****,   Management will provide additional updates shortly on its business plan, including continued webinars and how it expects revenue generation to progress.     Best,   Medivolve Inc. www.medivolve.ca
Comment by Frosted on Jun 12, 2021 8:26am
Not much of a concrete reply.. Going to take lots to get this stock out of the gutter. In the intrim, I suggest we refrain from speculating on revenue as we all know where that got us last time. Especially Hidden.
Comment by lscfa on Jun 12, 2021 1:14am
Slide 28 -  If we can get the formula right, our revenue model will dramatically improve – we’re projecting a potential upside from the $30 COVID testing cost per patient today, to $300 to $500 per patient – a game changer for our business and for communities across America.  
Comment by Catspajamas on Oct 26, 2021 7:54pm
You're not just a sperm guzzler, but you're a pathetically transparent sperm guzzler
Comment by knowsbest on Jun 15, 2021 9:58am
Loser # 2 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities